


HIV PREVENTION PIPELINE: PRODUCTS TO WATCH

PRECLINICAL	PHASE I	PHASE II	PHASE III	IMPLEMENTATION
Hundreds of...  ARV-Based  MPTs  Vaccine candidates  bNABs candidates	 3-Monthly DPV + LNG  On-Demand TAF + EVG  Vaccine candidates  Combo bNAB candidates	 On-Demand FTC/TAF  On-Demand TFV  Combo bNAB candidates	 Monthly AMI	 Daily TDF/FTC  Daily FTC/TAF  2-Monthly CAB  6-Monthly LEN  Monthly DPV
The US Govt's shut down of USAID ended six critical HIV research projects. With MATRIX, the field lost an important effort to develop diverse, on-demand, and multi-purpose products, especially for young women. The ADVANCE and BRILLIANT projects were researching a range of vaccine candidates while also building African-led research agendas.  Long-acting implants  Multi-purpose vaginal ring  Vaginal & mucosal inserts  Vaginal film  Vaccines		BIO-EQUIVALENCE  4-Monthly CAB  3-Monthly DPV  Weekly LEN *  12-Monthly LEN  Daily DPP		
KEY:  ARV-based  MPTs  Vaccines  bNABs AMI: Alimatravir, bNAB: broadly-neutralizing antibodies, CAB: Cabotegravir, DPP: dual prevention pill, DPV: Dapivirine, EVG: Elvitegravir, F/TAF: emtricitabine/tenofovir alafenamide, LEN: Lenacapavir, LNG: Levonorgestrel, TAF: tenofovir alafenamide, TDF/FTC: tenofovir disoproxil fumarate-emtricitabine * Weekly LEN has been submitted and is pending regulatory approval				